Antibacterial Agents TRIZ Cases

Mineral acid hydrolysis of specific plant extracts creates hydrolysates that combat antibiotic-resistant bacteria like MRSA.

Day-one vaccination bypasses maternal antibody interference, securing protection during the critical nursery exposure period and reducing ileitis pathology.

Pyridinium ionic liquid catalyzes one-pot imidazole synthesis.

Bacteriophage EK99P-1 selectively destroys E. coli type K99, resolving antibiotic resistance while sparing beneficial flora.

Purified DbpA antibodies eliminate cross-reactivity from whole cell extracts, resolving sensitivity and specificity trade-offs in Lyme disease diagnostics.

Composite heterocyclic structures inhibit beta-lactamase enzymes to overcome antibiotic resistance in bacterial infections.

Replacing galactose with glucose in glycosphingolipids resolves cytokine counterbalance to boost Th1 immunity.

RB51leuB strain expresses codon optimized Mycobacterium tuberculosis antigens via a marker free plasmid system.

Macrocyclic peptide structures overcome antibiotic resistance in Acinetobacter baumannii infections.

Crystalline salt forms resolve storage instability trade-offs while enabling deep lung delivery via dry powder formulations.

Complexing bitter actives with cation-exchange resin and hydrophilic adsorbents masks taste while ensuring rapid dissolution in acid media.

Soluble CD52 glycoprotein suppresses effector T-cell activation via Siglec-10 binding.

A vibrating membrane nebulizer generates pharmaceutical aerosols containing levofloxacin with controlled droplet sizes.

Bio-based microemulsions using lecithin and acidifiers maintain stability at extreme pH levels, replacing petroleum surfactants to reduce environmental harm.

Modular piperazine structures with tailored heterocyclic substituents inhibit CXCR3 activity to reduce lymphocyte recruitment in inflammatory diseases.

Antisense oligonucleotides targeting natural antisense transcripts up-regulate Adiponectin mRNA, resolving inadequate modulation of metabolic disease targets.

An Enterococcus-derived polypeptide elicits antibodies targeting peptidoglycan to overcome antibiotic resistance through opsonisation and complement activation.

Histidine-rich glycoprotein mediates neutrophil inactivity via preliminary binding, preventing elastase-induced tissue damage.

Bifidobobacterium breve DSM 32583 resolves colonization uncertainty in infant formulae by establishing stable microbiota and priming the immune system.

Succinic acid restores antibiotic efficacy against drug-resistant bacteria by boosting proton motive force for enhanced cellular uptake.

A universal anti-tag antibody binds to tagged binding agents to neutralize multiple disease agents.

A Bacillus subtilis 281 strain produces antimicrobial substances to inhibit respiratory pathogens.

Segmented in vitro glycosyltransferase processes correct recombinant peptide glycan structures, resolving scalability bottlenecks that cause immunogenicity.

High molecular weight glucose polymers shift immune profiles to extend protection duration while maintaining safety against pertactin-negative strains.

Anti-S. aureus alpha toxin antibodies neutralize cytotoxic effects, reducing bacterial load and preventing thromboembolic events in immunocompromised patients.

A rifaximin synthesis process using controlled precipitation to yield pseudo-crystalline material.

pH shock and freezing maturation steps prepare host cells for osmotic extraction, reducing proteolysis while increasing recombinant protein yield.

High temperature short time treatment inactivates probiotic bacteria while generating anti-inflammatory immune profiles.

Inhaled antibodies neutralize bacterial pathogens while probiotic immunomodulators enhance host defense against antibiotic-resistant infections.

Replaces rifamycin with bedaquiline in a macrolide regimen to improve efficacy against resistant strains while reducing side effects.

Formula one compounds inhibit beta-lactamases, restoring antibiotic efficacy against resistant bacteria through oral prodrug delivery.

Incubating inactive acid ceramidase precursor creates a mixture that extends half-life while maintaining therapeutic effectiveness.

Monoclonal antibodies target Staphylococcus aureus glucosaminidase to inhibit biofilm formation, addressing drug-resistant osteomyelitis recurrence.

Cyclodextrin compositions scavenge pesticides to reduce toxicity while maintaining parasite control efficacy.

Segmented delivery of TNF-α using PLA-PEG nanoparticles resolves systemic toxicity while maintaining anti-tumor efficacy.

A purified Hsp60 peptide induces antibodies that detect Ehrlichia infections via ELISA.

Engineered prokaryotic host cells produce stable bioconjugates through integrated chromosomal gene expression.

Chimeric nucleic acid molecules activate innate immunity through pattern recognition receptor binding.

Conservative amino acid substitutions in antibody framework regions reduce immunogenicity while maintaining binding affinity for IL-23p19.

Synthetic particles incorporating specific lipid antigens induce strong humoral and cellular immunity without antibiotic resistance risks.

Covalently attaching antimicrobial agents to amphiphilic hydrogel domains prevents leaching and degradation while maintaining cytocompatibility.

Cationic lipid adjuvants drive dual MHC pathway antigen presentation, resolving the trade-off between strain-specific protection and broad cross-immunity.

Benzoheterocyclic alkylamine compounds inhibit staphyloxanthin synthesis in Staphylococcus aureus.

A bioadhesive microparticulate carrier protects vaccine antigens during transit through the stomach and releases them at the intestinal mucosa.

A monoclonal antibody binds to a specific peptide sequence on the pathogen surface to block immunosuppressive functions.